HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience

類似資料

• Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
  著者:: London, Gérard, 等
  出版事項: (2018)
• Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
  著者:: Goldsmith, David, 等
  出版事項: (2018)
• Development and 10-year history of a biosimilar: the example of Binocrit(®)
  著者:: Aapro, Matti, 等
  出版事項: (2018)
• Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
  著者:: Aapro, Matti, 等
  出版事項: (2018)
• Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
  著者:: Aapro, Matti, 等
  出版事項: (2018)